Arcturus Therapeutics Q2 Results: Financials and update due Aug 6
Arcturus Therapeutics Holdings Inc. scheduled its Q2 2026 earnings release for Aug 6, 2026, after market close. The firm will host a concurrent conference call at 4:30 pm ET to discuss corporate updates. No financial metrics are provided in this notice, but the call may cover progress on its mRNA pipeline for rare diseases and pandemic vaccines.
*this image is generated using AI for illustrative purposes only.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6, 2026. The company, which develops messenger RNA medicines for liver and respiratory rare diseases, will simultaneously host a conference call and webcast at 4:30 pm Eastern Time to provide a corporate update. This announcement serves as an advance notice of the reporting date; no specific revenue, profit, or operational metrics are disclosed in the filing.
The earnings call offers investors a direct channel to management for insights into the company’s pipeline and strategic direction. Arcturus will present updates on its key therapeutic candidates and business collaborations during the session. The event is accessible via telephone or online webcast, ensuring broad investor participation.
Conference Call Details
Investors can access the conference call and webcast using the following information:
| Detail | Information |
|---|---|
| Date | Thursday, Aug 6, 2026 |
| Time | 4:30 p.m. ET |
| Domestic Dial-in | 1-800-347-6865 |
| International Dial-in | 1-203-518-9757 |
| Conference ID | ARCTURUS |
| Webcast | Available via company link |
Corporate Background and Pipeline
Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics focuses on developing therapeutics for rare diseases affecting the liver and respiratory systems. The company leverages three core enabling technologies: LUNAR lipid-mediated delivery, STARR self-amplifying mRNA technology, and expertise in mRNA drug substance and product manufacturing.
Arcturus previously developed KOSTAIVE, the first self-amplifying mRNA COVID vaccine approved globally. The company maintains an ongoing global collaboration with CSL Seqirus and U.S. BARDA for pandemic flu vaccines and operates a joint venture in Japan, ARCALIS, focused on manufacturing mRNA vaccines and therapeutics.
The current pipeline includes RNA therapeutic candidates targeting cystic fibrosis and ornithine transcarbamylase deficiency. Additionally, Arcturus has partnered mRNA vaccine programs for SARS-CoV-2 and influenza. Its versatile RNA platforms support multiple nucleic acid medicine types, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. The company’s intellectual property portfolio comprises over 500 patents and patent applications across the U.S., Europe, Japan, China, and other countries.
How might the clinical trial progress of Arcturus's cystic fibrosis and OTC deficiency candidates influence the company's valuation post-earnings?
What strategic shifts in capital allocation could investors expect if the Q2 2026 results indicate a need to extend the company's cash runway?
Will management provide updated timelines for regulatory submissions or pivotal trial readouts for its key liver and respiratory pipeline assets?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
